Enzo Q1 Revenues up 6 Percent, Reaches CDx Deal with Flagship Bio | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday a 6 percent drop in its FY 2014 revenues year over year.

Separately, the firm announced today a deal with Flagship Biosciences to develop companion diagnostics for anatomic pathology applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.